Summary of aGVHD by 100 days after allo-HSCT and 12 months after allo-HSCT, by grade and organ involvement
| aGVHD after allo-HSCT . | Vedolizumab 75 mg (n = 3), n . | Vedolizumab 300 mg (n = 21), n (%)/95% CI* . |
|---|---|---|
| By 100 d | ||
| Frequency of aGVHD by grade | ||
| Grade II | 0 | 3 (14.3)/3.8, 41.1 |
| Grade III | 0 | 1 (4.8)/0.6, 29.7 |
| Grade IV | 0 | 0 |
| Frequency of aGVHD by affected organ involvement† | ||
| Skin only | 0 | 1 (4.8) |
| Skin and intestinal tract | 0 | 2 (9.5) |
| Skin, intestinal tract, and liver | 0 | 1 (4.8) |
| Frequency of lower-intestinal aGVHD by stage | ||
| Stage 1 | 0 | 3 (14.3)/4.3, 38.0 |
| Stages 2 to 4 | 0 | 0 |
| By 12 mo | ||
| Frequency of aGVHD by grade | ||
| Grade II | 0 | 3 (14.3)/3.8, 41.1 |
| Grade III | 0 | 2 (9.5)/2.0, 35.6 |
| Grade IV | 0 | 0 |
| Frequency of aGVHD by affected organ involvement† | ||
| Skin only | 0 | 2 (9.5) |
| Skin and intestinal tract | 0 | 2 (9.5) |
| Skin, intestinal tract, and liver | 0 | 1 (4.8) |
| Frequency of lower-intestinal aGVHD by stage | ||
| Stage 1 | 0 | 2 (9.5)/2.1, 34.3 |
| Stage 2 | 0 | 1 (4.8)/0.6, 28.3 |
| Stages 3 to 4 | 0 | 0 |
| aGVHD after allo-HSCT . | Vedolizumab 75 mg (n = 3), n . | Vedolizumab 300 mg (n = 21), n (%)/95% CI* . |
|---|---|---|
| By 100 d | ||
| Frequency of aGVHD by grade | ||
| Grade II | 0 | 3 (14.3)/3.8, 41.1 |
| Grade III | 0 | 1 (4.8)/0.6, 29.7 |
| Grade IV | 0 | 0 |
| Frequency of aGVHD by affected organ involvement† | ||
| Skin only | 0 | 1 (4.8) |
| Skin and intestinal tract | 0 | 2 (9.5) |
| Skin, intestinal tract, and liver | 0 | 1 (4.8) |
| Frequency of lower-intestinal aGVHD by stage | ||
| Stage 1 | 0 | 3 (14.3)/4.3, 38.0 |
| Stages 2 to 4 | 0 | 0 |
| By 12 mo | ||
| Frequency of aGVHD by grade | ||
| Grade II | 0 | 3 (14.3)/3.8, 41.1 |
| Grade III | 0 | 2 (9.5)/2.0, 35.6 |
| Grade IV | 0 | 0 |
| Frequency of aGVHD by affected organ involvement† | ||
| Skin only | 0 | 2 (9.5) |
| Skin and intestinal tract | 0 | 2 (9.5) |
| Skin, intestinal tract, and liver | 0 | 1 (4.8) |
| Frequency of lower-intestinal aGVHD by stage | ||
| Stage 1 | 0 | 2 (9.5)/2.1, 34.3 |
| Stage 2 | 0 | 1 (4.8)/0.6, 28.3 |
| Stages 3 to 4 | 0 | 0 |
95% confidence intervals (CIs) were computed for the cumulative incidence of aGVHD by grade and were constructed using simultaneous CIs for multinomial proportions.37
Frequency of aGVHD by affected organ involvement is reported only for events of grade II to IV.
Grades of aGVHD are based on the modified Glucksberg criteria.